NCT01668537View on ClinicalTrials.gov

A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects

PHASE2CompletedINTERVENTIONAL

Enrollment

651

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

June 30, 2014

Conditions

Smallpox

Interventions

BIOLOGICAL

LF formulation of IMVAMUNE®

BIOLOGICAL

FD formulation of IMVAMUNE®

Trial Locations (3)

33143

Miami Research Associates, South Miami

40536

University of Kentucky, Lexington

66219

PRA, Lenexa

Sponsors

Lead Sponsor

Bavarian Nordic

All Listed Sponsors

lead

Bavarian Nordic

INDUSTRY

NCT01668537 - A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects | Biotech Hunter | Biotech Hunter